MENLO PARK, Calif.--(BUSINESS WIRE)--BioTrace Medical, Inc., the leader in innovative temporary cardiac pacing technology, today announced the company’s Tempo® Temporary Pacing Lead was featured in a patient case series presented at the Society of Cardiovascular Anesthesiologists’ 43rd Annual Meeting and Workshops, taking place virtually April 24-27.
The series titled “A Case Series of the BioTrace Medical Tempo Active Fixation Lead in Cardiac Surgery—A Novel Technique for Post-Surgical Pacemaking,” describes a collection of re-operative robotic mitral valve surgeries performed at Thomas Jefferson University Hospital in Philadelphia, Pa. in which the Tempo Lead was successfully utilized for temporary perioperative transvenous pacing. The cases demonstrate the ability of the Tempo Lead to provide reliable temporary pacing when epicardial lead placement is challenging.
The Tempo Lead’s unique design – featuring novel retractable stabilizers and a soft tip – mitigates the risks of dislodgment and perforation, ensures stability during rapid pacing and facilitates patient ambulation in recovery.
“Detection and treatment of cardiac perforation or tamponade caused by epicardial leads is particularly problematic because these events, while rare, usually happen during lead removal outside of the operating room and in a setting with limited hemodynamic monitoring,” said Jordan Goldhammer, M.D., Cardiothoracic Anesthesiologist and Director of Cardiovascular Peri-Procedural Clinical Operations at Sidney Kimmel Medical College at Thomas Jefferson University. “In my experience so far, the transvenous Tempo Lead is simple and safe to remove and has allowed our patients to safely ambulate and get to physical therapy sooner before discharge.”
With U.S. FDA clearance and CE certification, the Tempo Lead is the only active-fixation temporary transvenous pacing lead available in the world. The Tempo Lead has been used in more than 10,000 U.S. procedures with a safety and performance profile superior to conventional temporary leads, as exemplified by a 0.04% cardiac perforation or tamponade rate1 compared to temporary epicardial lead bleeding complication rates ranging from .75% to 1%.2,3
About BioTrace Medical
BioTrace Medical, Inc., a private venture-backed company based in Menlo Park, California, is dedicated to reinventing temporary pacing to improve patient outcomes and reduce hospital costs. For more information, visit www.biotracemedical.com.
1 Company data on file as of April 2021.
2 Cote CL, et al. J Card Surg. 2020.
3 Mahon L, et al. Am J Crit Care. 2012.
APM041-01.A
